Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835233 | 0.92 | EGFR (0.56) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL21835301 | 0.91 | EGFR (0.56) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL23406710 | 0.87 | EGFR (0.56) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL4861063 | 0.87 | EGFR (0.64) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL2255348 | 0.86 | EGFR (0.69) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL21835365 | 0.85 | EGFR (0.59) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL28689859 | 0.85 | AURKA (0.60) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL29944982 | 0.85 | EGFR (0.54) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL21835266 | 0.85 | EGFR (0.58) | EGFRERBB2LCKERBB3ERBB4 | |
| SCHEMBL4868109 | 0.84 | EGFR (0.65) | EGFRERBB2LCKERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885LCK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.